{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:52:04Z","timestamp":1789685524669,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150\u2009mg in patients with active PsA who had previous inadequate response\/intolerance to one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>KEEPsAKE 1 is an ongoing, global, phase 3 study with a 24-week, double-blind, placebo-controlled period (period 1) and an open-label extension period (period 2). In period 1, eligible patients were randomized 1:1 to receive subcutaneous risankizumab 150\u2009mg or placebo at weeks 0, 4 and 16. At week 24 (period 2), all continuing patients received open-label risankizumab 150\u2009mg every 12\u2009weeks through week 208.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 24, 57.3% of risankizumab-treated patients (n\u2009=\u2009483) achieved \u226520% improvement in ACR criteria (ACR20) vs 33.5% of placebo-treated patients (n\u2009=\u2009481; P\u2009&amp;lt;\u20090.001). At week 52, 70.0% of patients who were randomized to receive continuous risankizumab therapy and 63.0% of patients who were randomized to receive placebo in period 1 and then receive risankizumab at week 24 achieved ACR20. Similar result trends were observed for other efficacy measures. Risankizumab was well tolerated through 52\u2009weeks of treatment with a consistent safety profile from week 24 through week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with active PsA who were csDMARD-IR, continuous risankizumab treatment demonstrated robust long-term efficacy and was well tolerated through 52\u2009weeks of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, KEEPsAKE1, NCT03675308.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac607","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:53:54Z","timestamp":1666720434000},"page":"2113-2121","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-7102","authenticated-orcid":false,"given":"Lars Erik","family":"Kristensen","sequence":"first","affiliation":[{"name":"The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Keiserman","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Pontifical Catholic University, School of Medicine , Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research\u2013K Papp Clinical Research , Waterloo, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"McCasland","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Loyola University Medical Center , Maywood, IL, USA"},{"name":"Department of Veterans Affairs, Hines VA Hospital , Hines, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"White","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Waikato Hospital , Hamilton, New Zealand"},{"name":"Waikato Clinical School, University of Auckland , Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Lu","sequence":"additional","affiliation":[{"name":"AbbVie Inc ., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc ., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eldred","sequence":"additional","affiliation":[{"name":"AbbVie Inc ., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barcomb","sequence":"additional","affiliation":[{"name":"AbbVie Inc ., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD), Goethe University , Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"2023060113245429700_keac607-B1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2023060113245429700_keac607-B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023060113245429700_keac607-B3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2016-210963","article-title":"Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study","volume":"76","author":"Egeberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B4","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","article-title":"Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023060113245429700_keac607-B6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B7","first-page":"65","article-title":"GRAPPA treatment recommendations: an update from the 2020 GRAPPA Annual Meeting","volume":"97","author":"Coates","year":"2021","journal-title":"J Rheumatol Suppl"},{"key":"2023060113245429700_keac607-B8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2023060113245429700_keac607-B9","volume-title":"Prescribing information","author":"Skyrizi (risankizumab-rzaa","year":"2022"},{"key":"2023060113245429700_keac607-B10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B12","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"key":"2023060113245429700_keac607-B13","doi-asserted-by":"crossref","first-page":"A127","DOI":"10.1016\/j.jval.2016.03.519","article-title":"Evaluation of a novel clinician reported outcome in nail psoriasis [abstract]","volume":"19","author":"Hudgens","year":"2016","journal-title":". Value Health"},{"issue":"Suppl 2","key":"2023060113245429700_keac607-B14","first-page":"ii61","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B15","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the corrona psoriatic arthritis\/spondyloarthritis registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023060113245429700_keac607-B16","doi-asserted-by":"crossref","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"2023060113245429700_keac607-B17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"key":"2023060113245429700_keac607-B18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023060113245429700_keac607-B19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023060113245429700_keac607-B20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two\u2009years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"2023060113245429700_keac607-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000316169","article-title":"The burden of nail psoriasis: an introduction","volume":"221","author":"Baran","year":"2010","journal-title":"Dermatology"},{"key":"2023060113245429700_keac607-B22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2023060113245429700_keac607-B23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2023060113245429700_keac607-B24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023060113245429700_keac607-B25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","article-title":"Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study","volume":"7","author":"Smolen","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023060113245429700_keac607-B26","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac607\/47256450\/keac607.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2113\/50500861\/keac607.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2113\/50500861\/keac607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:36:30Z","timestamp":1685626590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/6\/2113\/6772502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,10,25]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac607","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,10,25]]}}}